BLAVIAL
Approved
Dec 2002
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
Drug data last refreshed 3d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HUMIRA (adalimumab) is a fully human monoclonal antibody that inhibits tumor necrosis factor (TNF-alpha), a key inflammatory cytokine. Approved in 2002, it treats 15 distinct indications spanning rheumatologic, dermatologic, gastroenterologic, and rare genetic diseases including rheumatoid arthritis, psoriasis, Crohn's disease, and multiple mucopolysaccharidoses. As a TNF inhibitor administered via subcutaneous injection, HUMIRA represents the foundational biologic therapy class for immune-mediated inflammatory diseases and remains a cornerstone treatment despite newer mechanism competitors.
$0.3BPart D
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Post - Marketing Case Registration Study on the Safety and Efficacy of Adalimumab Solution for Injection in Chinese Pediatric Patients With Moderate - to - Severe Active Crohn's Disease
Started May 2026
30 enrolled
Children Aged 6 Years and Above With Moderate - to - Severe Active Crohn's Disease
A Clinical Trail of Adalimumab in Treating Chinese Children With Severe Plaque Psoriasis
Started May 2026
30 enrolled
Severe Plaque Psoriasis in Chinese Children
A Study of Pharmacokinetics, Safety, and Immunogenicity of BCD-057 100 mg/mL, BCD-057 50 mg/mL, and Humira 100 mg/mL in Healthy Subjects
Started Mar 2025
444 enrolled
Healthy Adult Male
Comparison of Vedolizumab Treatment to Adalimumab Dose Intensification in Crohn's Disease Patients With Loss of Response or Biomarker Activity to Adalimumab on First Line With Therapeutic Drug Concentration.
Started Oct 2024
220 enrolled
Crohn's Disease
Fluorescence Imaging of IBD and RA Using Adalimumab-800CW
Started Aug 2024
36 enrolled
IBDRheumatoid Arthritis
Worked on HUMIRA at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.